- Home
- RPRX vs EXPE Comparison
RPRX vs EXPE Comparison
Compare RPRX & EXPE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | EXPE |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0B | 26.1B |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | RPRX | EXPE |
|---|---|---|
| Price | $52.97 | $218.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 29 |
| Target Price | $51.40 | ★ $275.89 |
| AVG Volume (30 Days) | ★ 2.8M | 1.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.90% | 0.77% |
| EPS Growth | N/A | ★ 9.61 |
| EPS | ★ 0.67 | N/A |
| Revenue | $2,378,193,000.00 | ★ $14,733,000,000.00 |
| Revenue This Year | $38.63 | $10.35 |
| Revenue Next Year | $4.73 | $6.93 |
| P/E Ratio | $79.66 | ★ N/A |
| Revenue Growth | 5.06 | ★ 7.61 |
| 52 Week Low | $32.15 | $156.05 |
| 52 Week High | $53.47 | $303.80 |
Technical Indicators
Market Signals| Indicator | RPRX | EXPE |
|---|---|---|
| Relative Strength Index (RSI) | 68.50 | 35.82 |
| Support Level | $35.35 | $211.23 |
| Resistance Level | N/A | $229.12 |
| Average True Range (ATR) | 1.08 | 9.12 |
| MACD | 0.21 | -4.31 |
| Stochastic Oscillator | 81.19 | 7.81 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About EXPE Expedia Group Inc.
Expedia is the world's second-largest online travel agency by bookings, offering services for lodging (80% of total 2024 sales), air tickets (3%), rental cars, cruises, in-destination, and other (10%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, but its three core online travel agency brands are Expedia, Hotels.com, and alternative accommodations brand Vrbo. It also has a metasearch brand, Trivago. Transaction fees for online bookings account for the bulk of sales and profits.